Advanced search
Publication Cover
Hematology Volume 26, 2021 - Issue 1
Submit an article Journal homepage
2,574
Views
5
CrossRef citations to date
0
Altmetric
Articles

Allogeneic hematopoietic stem cell transplantation could improve the survival of acute myeloid leukemia patients with ASXL1 mutations

Lili Zhoua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;b Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Jingnan Ana National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;b Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Chang Houa National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Zixuan Dinga National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Huiying Qiua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Xiaowen Tanga National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Aining Suna National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Suning Chena National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Yang Xua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;b Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, People’s Republic of ChinaView further author information
,
Tianhui Liua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;b Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected] [email protected]
View further author information
&
Depei Wua National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China;b Collaborative Innovation Center of Hematology, Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected] [email protected]
View further author information
 show all
Pages 340-347 | Published online: 10 Apr 2021

Figures & data

Figure 1. flowchart of patients for screening and follow-up.

Figure 1. flowchart of patients for screening and follow-up.

Table 1. Clinical characteristics of the 581 AML patients.

Table 2. Frequencies and distribution of the other mutation in the AML patients.

Figure 2. Survival outcomes for AML patients with different classification. (A) OS of AML patients with and without ASXL1 mutations; (B) DFS of AML patients with and without ASXL1 mutations; (C) OS of AML patients with and without ASXL1 mutations in intermediate/adverse group; (D) DFS of AML patients with and without ASXL1 mutations in intermediate/adverse group; (E) OS of CN-AML patients with and without ASXL1 mutations (F) DFS of CN-AML patients with and without ASXL1 mutations

Figure 2. Survival outcomes for AML patients with different classification. (A) OS of AML patients with and without ASXL1 mutations; (B) DFS of AML patients with and without ASXL1 mutations; (C) OS of AML patients with and without ASXL1 mutations in intermediate/adverse group; (D) DFS of AML patients with and without ASXL1 mutations in intermediate/adverse group; (E) OS of CN-AML patients with and without ASXL1 mutations (F) DFS of CN-AML patients with and without ASXL1 mutations

Figure 3. (A) OS of AML patients with ASXL1 mutations followed allo-HSCT or chemotherapy (B) DFS of AML patients with ASXL1 mutations followed allo-HSCT or chemotherapy.

Figure 3. (A) OS of AML patients with ASXL1 mutations followed allo-HSCT or chemotherapy (B) DFS of AML patients with ASXL1 mutations followed allo-HSCT or chemotherapy.

Table 3. Result of Univariable and multivariable analysis for OS and DFS in AML

Supplemental material

Supplemental Material

Download MS Word (360.5 KB)

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.